NCT00014313

Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

A Phase II Study to Evaluate the Role of Weekly Cisplatin With Oral Etoposide in Ewing's Sarcoma and Primitive Neuroectodermal Tumor (PNET) With Bone and/or Bone Marrow Metatstatic Disease

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: European Organisation for Research and Treatment of Cancer - EORTC · Network
• Sex: All
• Age: 15 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have metastatic Ewing's sarcoma or primitive neuroectodermal tumor.

Detailed description

OBJECTIVES: * Determine the activity of cisplatin and etoposide in terms of response of patients with metastatic Ewing's sarcoma or primitive neuroectodermal tumor. * Assess the bone marrow and kidney toxicity of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive cisplatin IV over 3 hours on days 1, 8, 15, 29, 36, and 43 and oral etoposide daily on days 1-15 and 29-43 in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 21-45 patients will be accrued for this study within 2 years.

Conditions

• Sarcoma

Interventions

Type	Name	Description
DRUG	cisplatin
DRUG	etoposide

Timeline

• Start date: 2001-01-01
• Primary completion: 2002-12-01
• First posted: 2003-01-27
• Last updated: 2012-09-24

Locations

1 site across 1 country: United Kingdom